Related Experiment Video

Updated: Jul 26, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Oncogenic Alterations of Metabolism Associated with Resistance to Chemotherapy

Fahimeh Ghasemi1,2, Tahereh Farkhondeh3, Saeed Samarghandian4

  • 1Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Current Molecular Medicine
|June 23, 2023
PubMed

Insights

Cancer cells reprogram metabolism for growth and spread. This review explores how glycolytic enzymes contribute to cancer progression and chemotherapy resistance, offering potential therapeutic targets.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Cancer cells exhibit metabolic reprogramming to support high proliferation, invasion, and metastasis.
  • Chemotherapy resistance in cancer is associated with significant changes in cellular metabolism.
  • Glycolytic enzymes are key players in these metabolic alterations.

Purpose of the Study:

  • To review the roles of specific glycolytic enzymes in cancer progression.
  • To discuss the involvement of glycolytic enzymes in chemotherapy resistance.
  • To highlight the potential of targeting glycolytic enzymes for cancer therapy.

Main Methods:

  • Literature review of studies on glycolytic enzymes in various cancer types.
  • Analysis of research linking metabolic alterations to cancer aggressiveness.
  • Examination of data on enzyme expression and chemotherapy response.

Main Results:

  • Glycolytic enzymes are frequently dysregulated in cancer, promoting proliferation and metastasis.
  • Altered expression and activity of these enzymes contribute to resistance against chemotherapy drugs.
  • Specific glycolytic enzymes show distinct roles in different cancer types.

Conclusions:

  • Glycolytic enzymes are critical mediators of cancer progression and therapeutic resistance.
  • Targeting these enzymes presents a promising strategy to overcome chemotherapy resistance.
  • Further research into specific glycolytic enzyme functions could lead to novel cancer treatments.
Keywords:
Chemotherapy resistancealdolaseenolaseglyceraldehyde 3-phosphate dehydrogenasehexokinaselactate dehydrogenase.phosphofructokinasephosphoglycerate kinasepyruvate kinase

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.6K